NYSE: VAPOVapotherm Inc Stock
$0.66+0.07 (+11.86%)
Updated Mar 31, 2023
VAPO Price
$0.66
Fair Value Price
N/A
Market Cap
$30.39M
52 Week Low
$0.46
52 Week High
$14.74
P/E
-0.16x
P/B
-1.08x
P/S
1.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$66.80M
Earnings
-$113.26M
Gross Margin
25.8%
Operating Margin
-152.1%
Profit Margin
-169.5%
Debt to Equity
-4.41
Operating Cash Flow
-$80M
Beta
0.54
Next Earnings
May 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A
VAPO Overview
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 276 full-time employees. The firm is focused on the development and commercialization of its high velocity nasal insufflations (Hi-VNI) technology products that are used to treat patients suffering from respiratory distress. Its Hi-VNI technology delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Its Precision Flow systems uses its Hi-VNI technology. The company offers three versions of its Precision Flow systems: Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its Precision Flow versions are integrated systems that provide precise user control of temperature, air flow and percentage oxygen through a one-button interface.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VAPO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VAPO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VAPO is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
VAPO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more VAPO due diligence checks available for Premium users.
Be the first to know about important VAPO news, forecast changes, insider trades & much more!
VAPO News
Valuation
VAPO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.16x
Industry
93.12x
Market
22.13x
VAPO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.08x
Industry
3.89x
VAPO's financial health
Profit margin
Revenue
$18.7M
Net Income
-$21.4M
Profit Margin
-114.9%
VAPO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VAPO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$96.2M
Liabilities
$124.4M
Debt to equity
-4.41
VAPO's short-term assets ($59.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VAPO's long-term liabilities ($104.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VAPO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VAPO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.9M
Investing
-$3.3M
Financing
$1.2M
VAPO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VAPO vs Medical Device Stocks
Vapotherm Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.